Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
Date:5/18/2010

xin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .



    SIMCERE PHARMACEUTICAL GROUP
    PRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
    (AMOUNTS EXPRESSED IN THOUSANDS, EXCEPT SHARE AND ADS DATA)

                                              Three months ended March 31,
                                            2009           2010        2010
                                             RMB            RMB         USD

    Product revenue                       436,633        457,648      67,047
    Other revenue                           5,873          1,021         150
    Total revenue                         442,506        458,669      67,197
    Cost of materials and production      (77,320)       (93,096)    (13,639)
    Gross profit                          365,186        365,573      53,558

    Operating expenses:
    Research and development expenses     (25,047)       (30,592)     (4,482)
    Sales, marketing and
     distribution expenses               (219,779)      (236,879)    (34,704)
    General and administrative
     expenses                             (59,288)       (67,240)     (9,851)
    Income from operations                 61,072         30,862       4,521

    Interest income                         2,569          1,296         190
    Interest 
'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Simceres Diosmectite API Passes EU-GMP Inspection
2. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
3. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
4. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
7. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
8. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
9. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
11. Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 GenSpera, Inc. ... the treatment of cancer, announces the recent publication of ... Steroids . The recent article co-authored ... the evolution and development of GenSpera,s prodrug technology platform that ... thapsigargin (from the plant Thapsia garganica ) directly ...
(Date:8/28/2014)... MONROVIA, Calif. , Aug. 28, 2014  STAAR Surgical ... and marketer of implantable lenses and delivery systems for the ... 2014 Health Care Conference at the New York Palace Hotel ... Barry Caldwell , President and CEO will ... financial results, and operational developments and be joined by ...
(Date:8/28/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... trials evaluating the use of collagenase clostridium histolyticum (CCH) for ... with a palpable cord will be presented at the upcoming ... Surgery of the Hand (ASSH) being held in ... (CCH) is a biologic approved in the U.S., EU, ...
Breaking Medicine Technology:GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3STAAR Surgical To Present At The Baird 2014 Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
... 25, 2007 - Reata,Pharmaceuticals, Inc. today announced ... company's Synthetic Triterpenoid programs in,the May 2007 ... The article, "Triterpenoids and rexinoids as multifunctional,agents ... by researchers,and Reata scientific collaborators from the ...
... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
Cached Medicine Technology:Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
(Date:8/28/2014)... To kick off the fall season ... One Spas retailers across the country are offering 0% ... The Hot Tub Tailgate Event is from August 29th-September ... more information and to apply early! , As the ... wide variety of outdoor hot tubs with exclusive features ...
(Date:8/28/2014)... 28, 2014) A fortuitous collaboration at Rice ... a recently discovered natural antibiotic. , The laboratory ... someday help bolster the fight against bacteria that ... around the world. , As part of ... structural biologist Yousif Shamoo and their colleagues created ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... be treated with nasal septum cells. Researchers at the ... cells taken from the nasal septum are able to ... can thus repair articular cartilage defects. The nasal cartilage ... environment is associated with the expression of so-called HOX ... has published the research results together with the report ...
(Date:8/28/2014)... OTTAWA, August 28, 2014 One in every 200 ... with the number of people living with the disease ... according to a study by researchers at the Institute ... Eastern Ontario (CHEO), and the Ottawa Hospital Research Institute. ... prevalence in the world. , The study, published this ...
Breaking Medicine News(10 mins):Health News:Synthesis produces new antibiotic 2Health News:Synthesis produces new antibiotic 3Health News:Synthesis produces new antibiotic 4Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2
... caries can destroy most of a child,s teeth by ... Indians and Alaskan natives. Although the link between ... has been known for almost a century, progress in ... the disease has remained elusive. The ...
... The American College of Physicians (ACP) today told the ... including enacting a permanent end to scheduled Medicare sustainable ... for Congress to act was demonstrated by today,s release ... across-the-board cut in Medicare payments to doctors on January ...
... , THURSDAY, Nov. 3 (HealthDay News) -- Allergy ... costs and can now provide relief to allergy sufferers ... And while allergy shots are currently given under the ... investigated, delegates heard at this week,s annual scientific meeting ...
... the first time, researchers have combined gene therapy ... severe, crippling bleeding disorder hemophilia A in large ... new therapies for human patients. Researchers at ... Medicine, collaborating with other institutions, report in ...
... HealthDay Reporter , WEDNESDAY, Nov. 2 (HealthDay News) -- ... subset of hard-to-treat hemophilia patients also seems to be effective ... this study, published in the Nov. 3 edition of the ... one and didn,t last long, the results do raise the ...
... Men with locally advanced or high-risk prostate cancer who ... are less likely to die from their disease, shows ... Margaret Hospital (PMH) Cancer Program, University Health Network. ... Lancet (doi: 10.1016/S0140-6736(11)61095-7). Principal investigator Padraig Warde, ...
Cached Medicine News:Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Congress must 'go big' on physician payment reform 2Health News:Congress must 'go big' on physician payment reform 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Gene therapy shows promise as hemophilia treatment in animal studies 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3Health News:Radiation plus hormone therapy greatly improves survival 2
... Unique product designed for LASIK surgery ... to irrigate the corneal interface and/or stromal ... the flap and helps elevate the flap ... 7/8in (.40 x 22mm) Formed 9mm from ...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 9mm from end. Two ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 25G x 7/8in (.50 ...
... Cannula tip is specially ... insertion through wound and manipulation ... x 3.5mm, flexible tubing 25cm, ... 2mm. Unique annular rings ...
Medicine Products: